We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+17%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$9.33B
AUM Growth
+$1.78B
(+24%)
Cap. Flow
+$552M
Cap. Flow
% of AUM
5.91%
Top 10 Holdings %
Top 10 Hldgs %
20.52%
Holding
814
New
78
Increased
378
Reduced
271
Closed
33
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$50.3M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$39.4M |
| 3 |
Intel
INTC
|
+$29.2M |
| 4 |
Qualcomm
QCOM
|
+$27.6M |
| 5 |
Danaher
DHR
|
+$26M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
|
+$49.9M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$41.6M |
| 3 |
ARQL
Arqule Inc
ARQL
|
+$26.5M |
| 4 |
Arrowhead Research
ARWR
|
+$24.9M |
| 5 |
Merck
MRK
|
+$15.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 30.73% |
| 2 | Technology | 19.55% |
| 3 | Financials | 10.18% |
| 4 | Consumer Discretionary | 9.32% |
| 5 | Communication Services | 8.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
376
Supernus Pharmaceuticals
SUPN
$2.73B
| $4.58M | 0.05% |
193,000
-99,000
| -34% | -$2.4M |
|
377
Veracyte
VCYT
$4.44B
| $4.56M | 0.05% |
163,391
+72,329
| +79% | +$1.87M |
|
378
Intercontinental Exchange
ICE
$84.1B
| $4.55M | 0.05% |
49,165
+1,382
| +3% | +$128K |
|
379
FedEx
FDX
$73.5B
| $4.54M | 0.05% |
29,995
+40
| +0.1% | +$6.17K |
|
|
ZAYO
380
DELISTED
Zayo Group Holdings, Inc.
ZAYO
| $4.52M | 0.05% |
+130,374
| New | +$4.46M |
|
381
Guardant Health
GH
$19.3B
| $4.51M | 0.05% |
57,752
+47,552
| +466% | +$3.43M |
|
|
BOLD
382
DELISTED
Audentes Therapeutics, Inc
BOLD
| $4.49M | 0.05% |
75,107
-225,693
| -75% | -$8.47M |
|
383
BorgWarner
BWA
$13.1B
| $4.48M | 0.05% |
117,245
-36,711
| -24% | -$1.35M |
|
|
NGM
384
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $4.47M | 0.05% |
242,000
+87,000
| +56% | +$1.27M |
|
385
Dow Inc
DOW
$20.8B
| $4.47M | 0.05% |
81,702
-3,150
| -4% | -$163K |
|
|
ARQL
386
DELISTED
Arqule Inc
ARQL
| $4.47M | 0.05% |
224,043
-2,281,194
| -91% | -$26.5M |
|
|
TGE
387
DELISTED
Tallgrass Energy, LP Class A Shares
TGE
| $4.44M | 0.05% |
+200,899
| New | +$3.85M |
|
|
XEC
388
DELISTED
CIMAREX ENERGY CO
XEC
| $4.44M | 0.05% |
84,548
+4,624
| +6% | +$215K |
|
|
TECD
389
DELISTED
Tech Data Corp
TECD
| $4.43M | 0.05% |
+30,877
| New | +$3.97M |
|
|
CISN
390
DELISTED
Cision Ltd. Ordinary Share
CISN
| $4.43M | 0.05% |
+444,262
| New | +$4.24M |
|
391
Vanda Pharmaceuticals
VNDA
$314M
| $4.37M | 0.05% |
266,000
-5,000
| -2% | -$75.6K |
|
392
SolarEdge
SEDG
$2.62B
| $4.35M | 0.05% |
45,781
+38,817
| +557% | +$3.32M |
|
|
SGMO
393
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $4.35M | 0.05% |
520,000
-95,000
| -15% | -$874K |
|
394
Tetra Tech
TTEK
$8.28B
| $4.34M | 0.05% |
251,755
+217,445
| +634% | +$3.77M |
|
395
Itron
ITRI
$3.76B
| $4.33M | 0.05% |
51,559
+44,354
| +616% | +$3.49M |
|
396
Genmab
GMAB
$17.7B
| $4.3M | 0.05% |
+192,622
| New | +$4.2M |
|
|
ACHN
397
DELISTED
Achillion Pharmaceuticals
ACHN
| $4.24M | 0.05% |
702,631
-262,369
| -27% | -$1.52M |
|
398
TransUnion
TRU
$14.9B
| $4.23M | 0.05% |
49,360
+35,261
| +250% | +$2.94M |
|
|
CMA
399
DELISTED
Comerica
CMA
| $4.22M | 0.05% |
58,764
+4,640
| +9% | +$319K |
|
400
Valero Energy
VLO
$90.5B
| $4.19M | 0.04% |
44,750
+22,164
| +98% | +$2.09M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q4 2019 Portfolio in Review
As of Q4 2019, Candriam SCA held 814 positions worth $9.33B, up 24% from $7.55B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Candriam SCA deployed $552M of net new capital in Q4 2019, opening 78 new positions and adding to 378 existing holdings. Its largest new stake was Vipshop: 2,005,000 shares worth $28.4M.
By sector, the portfolio is most concentrated in Healthcare at 31% of assets, down from 32% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Ra Pharmaceuticals, Inc. Common Stock, an estimated $49.9M trimmed.
- Candriam SCA's largest Q4 2019 buy was Vipshop: 2,005,000 shares worth $28.4M.
- Candriam SCA added most to Microsoft in Q4 2019, an estimated $50.3M increase.
- Candriam SCA's biggest Q4 2019 reduction was Ra Pharmaceuticals, Inc. Common Stock, cutting an estimated $49.9M.
- Candriam SCA fully exited Hilton Worldwide in Q4 2019, selling an estimated $11.8M.
- Candriam SCA's ten largest holdings make up 21% of its $9.33B portfolio in Q4 2019.
- Candriam SCA opened 78 new positions and closed 33 in Q4 2019.
- Candriam SCA's portfolio value rose 24% quarter-over-quarter to $9.33B.
Based on Candriam SCA's 13F filing for Q4 2019, filed 21 Jan 2020.